Consent Decree On Ranbaxy Expands U.S. FDA Oversight To India

By Daniel Poppy, Vikas Dandekar, Brenda Sandburg / Email the Authors / PharmAsia News Jan. 26, 2012 4:17 PM GMT
India / Word Count: 1614 / Article # 28120126009

Executive Summary

Ranbaxy set to lose 180-day exclusivity on three products, potentially five more as it begins process to meet new requirements.

Purchase this Article

$85.00 Buy Now

For $85.00, purchase this 1614-word article and receive immediate online access. 100% Satisfaction Guarantee.

Already a Subscriber?

Log in for complete access.

Questions?

Call Toll-Free (800) 332-2181 or +1 (908) 547-2159.

Log In

Email Address

Password

Remember Me

Forgot your password?

Don’t Have an Account?

If your employer has a site license, create your account to begin using it. Simply click ‘Create An Account’ button below to register now.

Otherwise, please explore our free content subscriptions.

Create an account

Enter the email address associated with your account and a temporary password will be sent to you.

Email Address

Need help? Contact us at (800) 332-2181, +1 (908) 547-2159, or custcare@elsevier.com

Email Article

* Required field

* To:

For multiple recipients, separate email addresses with a semi-colon.

* Your Name:

* Your Email:

Subject: Consent Decree On Ranbaxy Expands U.S. FDA Oversight To India

* Add a personalized message to your email:

Please Note: Only individuals with subscriptions to PharmAsia News will be able to access the full article. All other readers will be directed to the abstract and may purchase the article.

or Cancel

Consent Decree On Ranbaxy Expands U.S. FDA Oversight To India

Executive Summary

Purchase this Article

Already a Subscriber?

Questions?

Related Articles: 4

Elsevier Business Intelligence Publications

Offers & Events

Support Documents: 2

Elsevier Business Intelligence Publications

Topics Covered in this Article

Email Article